Whether the insulin-sensitizing effects of metformin may provide a way to increase the treatment efficacy of clinically available p110α inhibitors, or at least manage secondary hyperglycemia [122], should be answered by various ongoing clinical trials (NCT03006172, NCT04300790, NCT04899349) combining metformin with endocrine therapy and the PI3K inhibitors alpelisib and inavolisib. The gene discussed is INS; the disease is Hyperglycemia.